- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Patent holdings for IPC class A61P 9/10
Total number of patents in this class: 9257
10-year publication summary
|
271
|
378
|
536
|
476
|
558
|
609
|
521
|
514
|
504
|
119
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Daiichi Sankyo Company, Limited | 1879 |
121 |
| The Regents of the University of California | 20473 |
74 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3353 |
71 |
| Osaka University | 3332 |
61 |
| Shionogi & Co., Ltd. | 833 |
58 |
| Takeda Pharmaceutical Company Limited | 2728 |
53 |
| Sunshine Lake Pharma Co., Ltd. | 619 |
51 |
| Novartis AG | 10467 |
49 |
| Bristol-myers Squibb Company | 4817 |
49 |
| Amarin Pharmaceuticals Ireland Limited | 273 |
45 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 854 |
45 |
| Mitsubishi Tanabe Pharma Corporation | 531 |
39 |
| Bayer Pharma AG | 1034 |
38 |
| AstraZeneca AB | 2823 |
35 |
| Kowa Company, Ltd. | 1230 |
35 |
| Centre National de La Recherche Scientifique | 10841 |
32 |
| China Pharmaceutical University | 343 |
32 |
| Institut National de La Sante et de La Recherche Medicale (inserm) | 3107 |
32 |
| The University of Tokyo | 4304 |
32 |
| Boehringer Ingelheim International GmbH | 4571 |
31 |
| Other owners | 8274 |